CIAS
XBI icon

Capital Investment Advisory Services’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Capital Investment Advisory Services’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$323K Sell
2,044
-11
-0.5% -$1.49K 0.02% 564
2026
Q1 		$262K Sell
2,055
-68
-3% -$8.49K 0.02% 555
2025
Q4 		$259K Buy
2,123
+81
+4% +$9.29K 0.02% 548
2025
Q3 		$205K Sell
2,042
-400
-16% -$36K 0.02% 578
2025
Q2 		$203K Buy
2,442
+1,145
+88% +$91.3K 0.02% 560
2025
Q1 		$105K Hold
1,297
– – 0.01% 605
2024
Q4 		$117K Hold
1,297
– – 0.01% 550
2024
Q3 		$128K Sell
1,297
-1,333
-51% -$131K 0.01% 558
2024
Q2 		$244K Sell
2,630
-4,406
-63% -$395K 0.03% 442
2024
Q1 		$668K Sell
7,036
-2,183
-24% -$203K 0.07% 247
2023
Q4 		$823K Sell
9,219
-11,385
-55% -$845K 0.08% 213
2023
Q3 		$1.5M Buy
20,604
+584
+3% +$46.6K 0.15% 125
2023
Q2 		$1.67M Sell
20,020
-1,314
-6% -$110K 0.16% 108
2023
Q1 		$1.63M Sell
21,334
-1,876
-8% -$156K 0.19% 101
2022
Q4 		$1.93M Sell
23,210
-282
-1% -$22.8K 0.23% 85
2022
Q3 		$1.86M Sell
23,492
-5,361
-19% -$452K 0.24% 82
2022
Q2 		$2.14M Buy
28,853
+17,589
+156% +$1.32M 0.26% 77
2022
Q1 		$1.01M Buy
11,264
+2,804
+33% +$259K 0.11% 168
2021
Q4 		$947K Buy
8,460
+618
+8% +$74.5K 0.11% 183
2021
Q3 		$986K Buy
7,842
+2,609
+50% +$336K 0.12% 170
2021
Q2 		$709K Buy
5,233
+2,465
+89% +$324K 0.09% 218
2021
Q1 		$375K Buy
2,768
+1,018
+58% +$152K 0.05% 297
2020
Q4 		$246K Hold
1,750
– – 0.04% 375
2020
Q3 		$195K Buy
1,750
+50
+3% +$5.61K 0.04% 364
2020
Q2 		$190K Hold
1,700
– – 0.04% 318
2020
Q1 		$132K Buy
1,700
+38
+2% +$3.37K 0.03% 319
2019
Q4 		$158K Buy
1,662
+1,162
+232% +$101K 0.04% 315
2019
Q3 		$38K Hold
500
– – 0.01% 632
2019
Q2 		$43K Hold
500
– – 0.01% 592
2019
Q1 		$45K Sell
500
-475
-49% -$40.4K 0.02% 509
2018
Q4 		$70K Sell
975
-1,258
-56% -$101K 0.03% 385
2018
Q3 		$214K Sell
2,233
-358
-14% -$34.7K 0.1% 202
2018
Q2 		$247K Buy
2,591
+189
+8% +$17.4K 0.12% 174
2018
Q1 		$211K Buy
+2,402
New +$219K 0.12% 172

Other funds holding XBI

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
WAM
Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return
RFM
Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return
NHFG
New Harbor Financial Group Worcester, Massachusetts $633M AUM 37.53% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Capital Investment Advisory Services's XBI Position: Q2 2026 in Review

Capital Investment Advisory Services reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.54% in Q2 2026, selling an estimated $1.49K and leaving 2,044 shares worth $323K. The position accounts for 0.02% of the portfolio, ranked #564.

Capital Investment Advisory Services first reported a position in XBI in Q1 2018 and has held it in 34 quarters since. The position peaked at $2.14M in Q2 2022. 260 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Capital Investment Advisory Services held 2,044 shares of State Street SPDR S&P Biotech ETF worth $323K as of Q2 2026.
  • Capital Investment Advisory Services sold 11 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $1.49K.
  • State Street SPDR S&P Biotech ETF made up 0.02% of Capital Investment Advisory Services's portfolio in Q2 2026, its #564 holding.
  • Capital Investment Advisory Services first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 34 quarters since.
  • Capital Investment Advisory Services's State Street SPDR S&P Biotech ETF position peaked at $2.14M in Q2 2022.
  • 260 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.